rifamycin (aemcolo) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Rifamycin SV is a derivative of antibiotic rifamycin B (the natural fermentation product of S. mediterranei broths). The primary target of rifampicin on whole bacteria is the synthesis of RNA. Rifamycin belongs to the ansamycin class of antibacterial drugs and acts by inhibiting the beta subunit of the bacterial DNA-dependent RNA polymerase, blocking one of the steps in DNA transcription. This results in inhibition of bacterial synthesis and consequently growth of bacteria. Rifampicin exhibits bactericidal activity on Gram-positive and Gram-negative bacteria and on mycobacteria. Rifamycin SV MMX® (AEMCOLO), a non-absorbable rifamycin antibiotic formulated using the multi-matrix system, was designed to exhibit its pharmacological action on the distal small intestine and colon. AEMCOLO is indicated for the treatment of travelers’ diarrhea (TD) caused by non-invasive strains of Escherichia coli in adults.   NCATS

Chemistry

  • SMILES: CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)\C(=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(=O)C)[C@@H]1C)\C)cc(O)c4c3C2=O
  • InChIKey: HJYYPODYNSCCOU-ODRIEIDWSA-N
  • Mol. Mass: 697.78
  • ALogP: 4.75
  • ChEMBL Molecules:
    rifamycin  
    rifamycin sodium  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$9.6558 - $14.0550
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2-h)-dione, 21-acetate | cb-01-11 | otafa | r-75-1 | rifacin | rifamicina colirio | rifamicine sv | rifamycin | rifamycine chibret | rifamycin sodium | rifamycin sv | rifamycin sv, monosodium salt | rifamycin sv, sodium salt | rifocina | rifocyna | rifomycin | rifomycin sv

Organizations (14)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (1)


 

Dysentery (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Diarrhea (Phase 3)

Diverticulitis (Phase 2)

Gastrointestinal Diseases (Phase 2)

Healthy Volunteers (Phase 1)

Hepatic Encephalopathy (Phase 2)

HIV (Phase 3)

Intestinal Neoplasms (Phase 2)

Irritable Bowel Syndrome (Phase 2)

Liver Cirrhosis (Phase 2)

Pulmonary Medicine (Phase 4)

Tooth Abnormalities (Phase 4)

Tuberculosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue